DNDN Stock Chart

would approve the drug creating a gold mine for Dendreon Unfortunately for the longs it didn t happen and the stock plummeted from it s lofty heights Here s a look at the stock chart Without the revenue from sales of Provenge it looks like DNDN s financials will continue to remain in the red with the cost of ongoing additional clinical trials weighing heavily on the

would approve the drug creating a gold mine for Dendreon Unfortunately for the longs it didn t happen and the stock plummeted from it s lofty heights Here s a look at the stock chart Without the revenue from sales of Provenge it looks like DNDN s financials will continue to remain in the red with the cost of ongoing additional clinical trials weighing heavily on the

would approve the drug creating a gold mine for Dendreon Unfortunately for the longs it didn t happen and the stock plummeted from it s lofty heights Here s a look at the stock chart Without the revenue from sales of Provenge it looks like DNDN s financials will continue to remain in the red with the cost of ongoing additional clinical trials weighing heavily on the